Latest News and Press Releases

Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting Strong safety signals, including no cases of cytokine release syndrome, cell-related neurotoxicity,...

COMMUNIQUÉ Paris, le 6 décembre 2016 Interview vidéo Christian Homsy Directeur Général Celyad Celyad (Euronext Bruxelles etParis, et NASDAQ : CYAD), leader dans la découverte et...

MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...

First clinical trial of NKR-2 T-cells therapy completed with good safety outcome and unexpected signals of clinical activity at the low doses tested Strong cash management leading to a cash runway...

MONT-SAINT-GUIBERT, Belgium, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...

MONT-SAINT-GUIBERT, Belgium, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...

 Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level No safety issues or dose limiting toxicity reported. The trial was a single...

MONT-SAINT-GUIBERT, Belgium, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of cell therapies, today announced its...

No safety issues or dose limiting toxicity reported in the first patient at the fourth dose level. Next patient, 11th of the trial, has been infused. The trial is a dose escalation study...

Celyad grants an exclusive license to ONO for the development and commercialization of Celyad's unique allogeneic NKR-2 T-cell in Japan, Korea and Taiwan. Celyad also grants to ONO an...